Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by OvaScience, Inc. on June 26, 2018. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, executive compensation, and director compensation policies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results.
Material Changes and Voting Results
A quorum of 28,541,695 shares (79.82% of outstanding shares) was present at the meeting. The following actions were approved:
- Director Elections: Christopher Kroeger, M.D., M.B.A., and Jeffrey D. Capello were reelected as Class III directors until the 2021 annual meeting.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Executive Compensation: The compensation of named executive officers was approved on an advisory basis.
- Director Compensation: The 2018 Non-Employee Director Compensation Policy was adopted.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the annual meeting proceedings.
Key Facts for Investor Verification
- Verify the total number of shares eligible to vote (35,758,907) versus the quorum achieved (28,541,695).
- Confirm the specific vote counts for the ratification of Ernst & Young LLP (26,752,093 For vs. 336,459 Against).
- Note the significant number of broker non-votes on director elections and executive compensation (13,858,693 each), indicating shares held by brokers that were not voted on these specific matters.
- Confirm the term end date for the reelected directors (2021 annual meeting).